2 min readNew Theranostic Approach Reduces Tumour Volume and Increases Survival in NET Study
Reston, VA — A pair of copper radionuclides that target the somatostatin receptor overexpressed in neuroendocrine tumours has proven successful in identifying tumors and improving survival. According to new research published in the December issue of The Journal of Nuclear Medicine, the imaging agent 64Cu-CuSarTate produced high-quality positron emission tomography (PET) images in a mouse model of neuroendocrine tumours, while its therapeutic counterpart, 67Cu-CuSarTate, was highly effective in reducing tumour volume and extending lifespan. The research also demonstrated the advantages of delivering the radionuclide therapy as two fractionated doses, as opposed to one.
Neuroendocrine tumours typically are diagnosed with 68Ga-DOTA-octreotate and treated with 177Lu-LuTATE peptide receptor radionuclide therapy. However, using two different chemical elements (Ga and Lu) can lead to inconsistent tissue biodistribution, as they do not have the same binding and internalizations interactions. “Ideally, a chemically identical ‘imaging-therapeutic’ pair of radionuclides bound to the same targeting agent should be used for diagnosis and treatment,” said Dr. Paul S. Donnelly, professor in the School of Chemistry at the University of Melbourne in Melbourne, Victoria, Australia.
In the study, researchers utilized a preclinical mouse model to explore the chemically identical radionuclide pair 64Cu-CuSarTate and 67Cu-CuSarTate. To assess the ability of 64Cu-CuSarTate to positively identify tumours, PET imaging occurred at one hour and four hours after injection of the radiotracer. On completion of the four-hour imaging, mice were euthanized and biodistribution studies were performed.
Multiple therapy experiments were also performed to evaluate the efficacy of 67Cu-CuSarTate. In the first, mice were injected with five MBq of 177Lu-LuTATE, five MBq of 67Cu-CuSarTate or saline and monitored for tumour growth. In the second experiment, mice were injected with a total of 30 MBq of 177Lu-LuTATE, 67Cu-CuSarTate or saline either as a single intravenous injection or as two 15 MBq fractions, two weeks apart; tumour growth was then monitored.
64Cu-CuSarTate PET images acquired at both one hour and four hours post-injection revealed very high tumour uptake and excellent tumour-to-background ratios. The high tumour uptake was confirmed with the ex vivo biodistribution analysis. Tumour growth was inhibited by 75 percent with 67Cu-CuSarTate treatment and by 89 percent with 177Lu-LuTATE, and survival was extended from 12 days in the control group to 21 days following treatment with both therapies. Treatment of tumours with two fractions of either 177Lu-LuTATE or 67Cu-CuSarTate significantly improved survival when compared to delivery as a single fraction. Equivalent efficacy was observed between the two therapies following treatment on both the single and fractionated schedules.
“Copper radionuclides are beneficial for several reasons,” said Dr. Rodney J. Hicks, professor in the Sir Peter MacCallum department of oncology at the University of Melbourne, in Melbourne, Victoria, Australia. “The strong binding of copper within the tumour allows for increased detection of disease, which can serve to limit radiation exposure to normal tissues during therapy. The ability to image at multiple time points with 64Cu-CuSarTate supports prospective dosimetry for therapeutic treatment planning with 67Cu-CuSarTATE, which could potentially offer shorter cycling of treatment, particularly for more aggressively growing tumours.”
In terms of potential translation of the copper-64/67 theranostic pair to clinical studies, it is pertinent that copper-64 is produced in a cyclotron. The longer half-life of 64Cu-CuSarTATE as compared to 68Ga-DOTA-octreotate means that the tracer can be easily produced under good manufacturing practice conditions and transported regionally. 67Cu-CuSarTATE can be produced with linear-accelerators in high specific activity and radionuclide purity, so it is not reliant on nuclear reactors.
“Looking to the future of molecular imaging and nuclear medicine, the chemistry and general concepts presented in this study could be expanded to other peptides that target different receptors, as well as antibodies and engineered antibody fragments. This offers the potential to provide diagnostic imaging using copper-64 to plan individualized treatments with copper-67 agents for a wide range of cancer patients,” noted Donnelly.
Article adapted from a Society of Nuclear Medicine and Molecular Imaging news release.
Publication: Peptide Receptor Radionuclide Therapy with 67Cu-CuSarTATE Is Highly Efficacious Against a Somatostatin-Positive Neuroendocrine Tumor Model. Cullinane, C et al. The Journal of Nuclear Medicine (December 01, 2020): Click here to view.